Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
Post-hoc analysis (251 participants with albuminuria at baseline) found that dapagliflozin improved urinary albumin-to-creatinine ratio vs placebo over 52 weeks (difference in change from baseline vs placebo = -31.1% for 10 mg, p<0.05).
Source:
The Lancet Diabetes & Endocrinology
SPS commentary:
Authors state the data suggest dapagliflozin may provide renoprotective benefits in individuals with type 1 diabetes and albuminuria. A related commentary concludes that the study contributes to proof of concept for renoprotection for this class of drug in type 1 diabetes and helps support the benefit rather than the risk of treatment. However, adequately powered trials based on clinical outcomes are clearly still required for the use of these and other adjunct therapies in type 1 diabetes.